NCT01714609View on ClinicalTrials.gov

The Effect of Sorafenib on Portal Pressure

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2014

Conditions
Clinically Significant Portal Hypertension
Interventions
DRUG

Placebo

Placebo Comparator: Placebo

DRUG

Sorafenib

Sorafenib, 400 mg twice daily

Trial Locations (6)

10016

New York University Langone Medical Center, New York

19104

University of Pennsylvania School of Medicine, Philadelphia

77030

The University of Texas Health Science Center at Houston, Houston

06520

Yale Cancer Center, New Haven

06516

VA Medical Center West Haven, West Haven

02115

Brigham & Womens, Boston

Sponsors

Collaborators (1)

Onyx Therapeutics, Inc.
All Listed Sponsors
collaborator

Onyx Therapeutics, Inc.

INDUSTRY

lead

Yale University

OTHER